Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
NCT Number: NCT01704937
Fecal microbiota transplantation (FMT) is the reconstitution of normal flora by a "stool transplant" from a healthy individual to a C. difficile-infected recipient, and has long been a successful approach to recurrent/refractory C. difficile. The purpose of this project is to generate a frozen FMT inoculum from well-screened healthy volunteer donors which can be used repeatedly, particularly in those who do not have a healthy intimate partner or other related donor. Delivery of FMT has been performed colonoscopically, by fecal retention enema, or by the nasogastric route. This study will evaluate the safety and secondarily the efficacy of a frozen inoculum administered by nasogastric tube vs administered by colonoscope.
Subjects with recurrent/relapsing C. difficile infection (10 per group) will receive FMT via either:
* colonoscopy * NGT
The primary endpoint is assessment of safety as measured by clinical events (GI, procedural, systemic). Efficacy will be defined as a resolution of diarrhea off antibiotics for C. difficile, in the absence of a need for OTHER systemic antibiotics, i.e. resumption of a normal bowel status for the individual. Secondary efficacy endpoints include weight, subjective well-being and relative clinical improvement per standardized questionnaire, and subject qualitative assessment of, and satisfaction with, the transplant procedures. Subjects will be monitored for clinical safety by history and standard exams and the follow-up questionnaire as well as followed closely by phone and in person.
Looking for future studies?
Notify Me7 year–90 year
All sexes
Interventional
Phase 1
Boston, Massachusetts, 02114, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Reconstitution of normal flora by a "stool transplant" from a healthy individual to a C. difficile - infected recipient via colonoscopy or nasogastric tube
Time frame: up to 6 mo post FMT
Safety is assessed by clinical symptoms, exam, signs (GI and systemic)
Time frame: 3 months
Efficacy is defined as resolution of C. Difficile signs and symptoms off antibiotics for C. difficile
Massachusetts General Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03931941
Bacterial Infections, Bacterial Infections and Mycoses
Phoenix, Arizona, United States
View Trial DetailsNCT01598311
Bacterial Infections, Bacterial Infections and Mycoses
View Trial DetailsNCT01670149
Bacterial Infections, Bacterial Infections and Mycoses
Nottingham, Nottinghamshire, United Kingdom
View Trial DetailsNCT03388268
Bacterial Infections, Bacterial Infections and Mycoses
St Louis, Missouri, United States
View Trial Details